Imatinib mesylate has anti-inflammatory properties, because it is a specific and potent inhibitor of several protein tyrosine kinases. Paniagua et al. have investigated imatinib's mechanism of ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

About IMKELDI IMKELDI is an oral solution of imatinib mesylate, a tyrosine kinase inhibitor, approved by the U.S. Food and Drug Administration for use in certain forms of leukemia (such as acute ...

IMKELDI offers a liquid formulation of imatinib mesylate, a tyrosine kinase inhibitor. It is designed for use in adults and paediatric patients as young as one, targeting acute lymphoblastic ...

Thus, FDG-PET is a good predictor of response in GISTs and is able to assess treatment response very early after initiating treatment with imatinib mesylate. Metabolic changes in the tumor seem to ...